Pattern BioSciences develops DNA computers that execute molecular programs to identify and target disease-specific cellular patterns with high precision. This technology enables tailored therapies that can eliminate or reprogram cells, addressing complex diseases at their root cause without the adverse effects associated with traditional treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development faces challenges in addressing diseases with complex molecular profiles, often relying on treatments that lack the precision to target affected cells without harming healthy tissue. Many key disease drivers are also considered "undruggable" by conventional small molecule or biologic therapies. This limitation hinders the development of effective therapies for intractable conditions.
Solution
Pattern BioSciences develops DNA computers that operate within cells to identify and target disease-specific molecular patterns. The DNA computers consist of a sense module that interacts with cellular inputs, a compute module that executes a program based on those inputs, and a respond module that activates a therapeutic effector. By analyzing genomics, transcriptomics, and proteomics data, Pattern BioSciences designs molecular programs that can eliminate or reprogram cells based on their unique molecular signatures. This approach enables the creation of tailored therapies that address diseases at their root cause with greater precision and reduced toxicity.
Target Audience
The primary target audience includes researchers and clinicians focused on developing targeted therapies for complex diseases, particularly those currently considered intractable or undruggable.
Features
- Molecular programs designed from multi-omic data to target specific cellular profiles.
- DNA computers with sense, compute, and respond modules for executing therapeutic programs within cells.
- Ability to target "undruggable" inputs such as transcription factors, microRNAs, promoters, and enhancers.
- Streamlined design process for generating therapeutic candidates with shorter timescales and reduced costs.
- _In vitro_ and _in vivo_ disease models that recapitulate patient molecular patterns for preclinical testing.